Charles River Laboratories (CRL) Stock News
$CRL · NYSE · HEALTHCARE · 4 stories in 30 daysBORSA has published 4 stories on Charles River Laboratories (CRL) in the past 30 days, 1 of them high impact. BORSA’s news read on CRL is bullish at 61/100, −1 over 24 hours, based on 3 company events over the past 30 days. CRL last closed at $301.79 on Oct 9, up 4.00% over five sessions and up 10.55% over the past month. Charles River Laboratories’ next earnings report is scheduled for Wednesday, Nov 4.
The wire on $CRL
newest first · updated · direct subject stories onlyCharles River Laboratories (CRL) and Autolomous announced Apollo Orchestrate, a digital lab execution system built on Autolomous's autoloMATE platform. The system digitizes sample-to-release workflows for GMP QC testing at Biologics sites in North America and Europe, replacing paper records and improving efficiency and client transparency.
bullish 65 · impact 30CRL at $306.29, up 5.55%. On pace for highest close since Feb. 15, 2022. Up 53.54% YTD. Fourth-best S&P 500 performer today.
· impact 70
